PURPOSE: To retrospectively determine the distribution of stage I lung cancer growth rates with serial volumetric computed tomographic (CT) measurements. MATERIALS AND METHODS: This study was institutional review board approved and HIPAA compliant. The informed consent requirement was waived. Patients (n = 149) with stage I lung cancer who underwent two pretreatment CT examinations 25 or more days apart were identified. At the first and last examinations, tumor perimeters were manually inscribed by using software tools and the cross-sectional area was calculated. To calculate tumor volume, the summed areas were multiplied by the section increment and a formula was applied to reduce partial volume effects. Doubling time (DT) was calculated by using the volume and interscanning interval. The percentages of tumors that would surpass volume increase thresholds of 5%-25% for detectable growth at different time intervals were calculated. Age at diagnosis was compared with the reciprocal of DT, time interval between CT examinations, and initial tumor volume by using Pearson correlation. P < .05 denoted statistical significance. RESULTS: Lung cancer was stage IA in 99 patients and stage IB in 50. Median patient age was 72 years, and median interscanning interval was 130 days. Median tumor volumes were 3000 and 6213 mm3 at the first and last examinations, respectively. Median DT was 207 days; 21 tumors did not increase in volume between examinations. The interscanning interval required for 90% of growing tumors to surpass the growth threshold ranged from 8 weeks (5% threshold) to 37 weeks (25% threshold). Fifty-three percent of growing tumors would surpass the 25% threshold at 8 weeks, and 95% would surpass it at 1 year. Age at diagnosis was negatively correlated with growth rate (P = .047); there was no correlation between growth rate and either age at diagnosis or interscanning interval. CONCLUSION: At serial volumetric CT measurements, there was wide variability in growth rates. Some biopsy-proved cancers decreased in volume between examinations.
PURPOSE: To retrospectively determine the distribution of stage I lung cancer growth rates with serial volumetric computed tomographic (CT) measurements. MATERIALS AND METHODS: This study was institutional review board approved and HIPAA compliant. The informed consent requirement was waived. Patients (n = 149) with stage I lung cancer who underwent two pretreatment CT examinations 25 or more days apart were identified. At the first and last examinations, tumor perimeters were manually inscribed by using software tools and the cross-sectional area was calculated. To calculate tumor volume, the summed areas were multiplied by the section increment and a formula was applied to reduce partial volume effects. Doubling time (DT) was calculated by using the volume and interscanning interval. The percentages of tumors that would surpass volume increase thresholds of 5%-25% for detectable growth at different time intervals were calculated. Age at diagnosis was compared with the reciprocal of DT, time interval between CT examinations, and initial tumor volume by using Pearson correlation. P < .05 denoted statistical significance. RESULTS: Lung cancer was stage IA in 99 patients and stage IB in 50. Median patient age was 72 years, and median interscanning interval was 130 days. Median tumor volumes were 3000 and 6213 mm3 at the first and last examinations, respectively. Median DT was 207 days; 21 tumors did not increase in volume between examinations. The interscanning interval required for 90% of growing tumors to surpass the growth threshold ranged from 8 weeks (5% threshold) to 37 weeks (25% threshold). Fifty-three percent of growing tumors would surpass the 25% threshold at 8 weeks, and 95% would surpass it at 1 year. Age at diagnosis was negatively correlated with growth rate (P = .047); there was no correlation between growth rate and either age at diagnosis or interscanning interval. CONCLUSION: At serial volumetric CT measurements, there was wide variability in growth rates. Some biopsy-proved cancers decreased in volume between examinations.
Authors: Fabien Maldonado; Jennifer M Boland; Sushravya Raghunath; Marie Christine Aubry; Brian J Bartholmai; Mariza Deandrade; Thomas E Hartman; Ronald A Karwoski; Srinivasan Rajagopalan; Anne-Marie Sykes; Ping Yang; Eunhee S Yi; Richard A Robb; Tobias Peikert Journal: J Thorac Oncol Date: 2013-04 Impact factor: 15.609
Authors: Jingbo Wang; Pawinee Mahasittiwat; Ka Kit Wong; Leslie E Quint; Feng-Ming Spring Kong Journal: Lung Cancer Date: 2012-07-28 Impact factor: 5.705
Authors: Rebecca M Lindell; Thomas E Hartman; Stephen J Swensen; James R Jett; David E Midthun; Jayawant N Mandrekar Journal: Chest Date: 2009-07-06 Impact factor: 9.410
Authors: Michael K Gould; Jessica Donington; William R Lynch; Peter J Mazzone; David E Midthun; David P Naidich; Renda Soylemez Wiener Journal: Chest Date: 2013-05 Impact factor: 9.410